Image

Middle East and Africa Leber Congenital Amaurosis Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Middle East and Africa Leber Congenital Amaurosis Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Apr 2022
  • MEA
  • 350 Pages
  • No of Tables: 126
  • No of Figures: 37

Middle East and Africa Leber Congenital Amaurosis Market, By Disease Type (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales) Industry Trends and Forecast to 2029.

Middle East and Africa Leber Congenital Amaurosis Market

 Market Analysis and Insights

Middle East and Africa leber congenital amaurosis market is driven by the factors such as an increase in the prevalence of chronic diseases such as diabetes & gastrointestinal disorders, a growing number of the up-coming players and the popularity of infusion pumps in-home care services, which enhance its demand, as well as increasing investment in research and development, leads to the market growth. Currently, various research studies are taking place, which is expected to create a competitive advantage for manufacturers to develop new and innovative leber congenital amaurosis treatments and therapies, which is expected to provide various other opportunities in the leber congenital amaurosis market. However, the strict government regulations on approval and device errors during infusion therapy are expected to hamper the growth.

Leber Congenital Amaurosis Market

Leber Congenital Amaurosis Market

Middle East and Africa leber congenital amaurosis market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal to rising preference among customers due to guaranteed payment and high international sales of the product are the major drivers which propelled the demand of the market in the forecast period.

Middle East and Africa leber congenital amaurosis market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that Middle East and Africa leber Congenital Amaurosis Market will grow at a CAGR of 2.7% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

By Disease Type (Infantile Type, Juvenile Type And Other), Type(Therapy, Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare And Others), Distribution Channel (Direct Tender And Retail Sales)

Countries Covered

By Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa)

Market Players Covered

Invitae Corporation, Spark Therapeutics, Inc., LKC Technologies, CENTOGENE N.V., Optos, Metrovision, Blue Print Genetics Oy (A Subsidiary of Quest Diagnostics), CD Genomics, ProQR Therapeutics, OCUGEN, INC., MeiraGTx Limited, Coave Therapeutics, IVERIC bio, Inc. , Atsena Therapeutics, Editas Medicine, Eluminex Biosciences, Okuvision, Astellas Pharma Inc., Allergan, agtc, Gyroscope Therapeutics Limited, SparingVision, Kubota Pharmaceutical Holdings Co. Ltd., REGENXBIO Inc. among others.

Middle East and Africa Leber Congenital Amaurosis Market Dynamics

Drivers

  • Increase in incidence and prevalence of rpe65 gene-mediated in retinal diseases

Inherited retinal dystrophies (IRDs) represent a genetically diverse group of progressive, visually debilitating diseases. Adult and pediatric patients with vision loss due to IRD caused by biallelic mutations in the 65-kDa retinal pigment epithelium (RPE65) gene are often clinically diagnosed as retinitis pigmentosa (RP), and leber congenital amaurosis (LCA).

Leber congenital amaurosis (LCA) is an eye disorder that primarily affects the retina. LCA is characterized by severe visual impairment from birth or the first few months of life, roving eye movements or nystagmus, poor pupillary light responses, oculo digital sign (poking, rubbing, and/or pressing of the eyes), and undetectable or severely abnormal full-field electroretinogram (ERG). LCA is usually inherited as an autosomal recessive genetic condition.

  • Increase in pipeline products and clinical trials

The continuous innovation for the treatment of inherited retinal diseases and leber congenital amaurosis disorder has the potential to positively impact the market as the size of the market will increase, when these products will have approved in the market. Due to no pharmacological treatments for the LCA the major market players are continuously innovating the treatment or investing in the R&D for the treatment. Various ongoing clinical trials are recruiting worldwide to find the mechanism of diseases for treatment.

Opportunities

  •  Increase in government initiatives toward leber congenital amaurosis

According to WHO, the prevalence of monogenic IRDs is it affects about 1 in 40,000 newborns ly. To prevent these, the government of several countries across the globe have taken initiatives.

The various programs and decisions taken by the government around the world for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the leber congenital amaurosis market.

Restraints/Challenges

The cost of the product plays a major factor in the market. In the inherited retinal diseases market, it is generally observed that the cost of the products is highly sophisticated, need to be precise, and other specifications increase the product's cost.

The high cost of the treatment is due to the various checkpoints of the treatment along with the use of high-tech modalities to perform such treatment procedures.

However, the hospital care further adds to the cost of the leber congenital amaurosis. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with leber congenital amaurosis treatment and diagnosis is expected to restrain the leber congenital amaurosis market growth.

Whereas the European Medicines Agency does not. Gene therapy products are regulated by FDA’s Center for Biologics Evaluation and Research (CBER). FDA requires the submission of an IND before initiating clinical studies, and an approved biologics license application (BLA) to market the product in the United States. The regulatory framework for the development and manufacturing of gene therapy products comprises reg­ulations and guidance documents, including the interpretation of these governing documents by regulators.

However, every country is bounded by the guidelines regulated by different authorities which are expected to act as a challenge to the growth of the leber congenital amaurosis market.

Recent Development

  • In March 2022, SparingVision announced that it will be presenting data on its lead product candidate SPVN06 and the natural history of retinitis pigmentosa, its core focus indication, at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting. This has helped the company to showcase its progress on pipeline products.

Middle East and Africa Leber Congenital Amaurosis Market Divide

Middle East and Africa leber congenital amaurosis market is categorized into five notable segments which are based on disease type, type, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Disease Type

  • Infantile Type
  • Juvenile Type
  • Others

On the basis of disease type, the leber congenital amaurosis market is segmented into infantile type, juvenile type & others

Type

  • Diagnosis
  • Therapy

On the basis by type, the leber congenital amaurosis market is segmented into diagnosis and therapy. Diagnosis segment is further segmented into clinical diagnosis and genetic diagnosis. Clinical diagnosis is further segmented into clinical eye examination, visual field test, retail imaging, and electro physiological tests. Clinical diagnosis is sub-segmented into electrophysiological tests, retinal imaging, visual field test and clinical eye examination. Electrophysiology tests is subsegmented into full-field electroretinogram (ERG) and dark adaptometry (DA). Retinal imaging is subsegmented into optical coherence tomography (OCT), fundus autofluorescence imaging (FAF), scanning laser ophthalmoscopy (SLO) and adaptive optics (AO) imaging and conventional color fundus imaging. Visual field tests is sub-segmented into computerized visual field tests and manual field test. Clinical examination is sub-segmented into slit lamp, indirect ophthalmoscopy, refraction test and dilation exam. Therapy segment is further segmented into gene therapy, retinal therapy, neuroprotective agents, and others. Gene therapy is further segmented into luxturna and others. Neuroprotective agents are further segmented into vitamin A palmitate, docosahexaenoic acid (DHA), lutein, and others.

End User

  • Hospitals
  • Specialty clinics
  • Ambulatory surgical centers
  • Home healthcare
  • Others

On the basis of end user, the leber congenital amaurosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others.

Distribution Channel

  • Retail Sales
  • Direct Tender

Leber Congenital Amaurosis Market

On the basis of distribution channel, the leber congenital amaurosis market is segmented into retail sales, direct tender.

Leber Congenital Amaurosis Market Regional Analysis/Insights

The leber congenital amaurosis market is analyzed and market size insights and trends are provided by country, disease type, type, end user, and distribution channel as referenced above.

The countries covered in the leber congenital amaurosis market report are Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa.

South Africa is expected to dominate due to increasing strategic initiative by key player.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Leber Congenital Amaurosis Market Share Analysis

Middle East and Africa leber congenital amaurosis market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus leber congenital amaurosis market.

Some of the major players are Invitae Corporation, Spark Therapeutics, Inc., LKC Technologies, CENTOGENE N.V., Optos, Metrovision, Blue Print Genetics Oy (A Subsidiary of Quest Diagnostics), CD Genomics, ProQR Therapeutics, OCUGEN, INC., MeiraGTx Limited, Coave Therapeutics, IVERIC bio, Inc. , Atsena Therapeutics, Editas Medicine, Eluminex Biosciences, Okuvision, Astellas Pharma Inc., Allergan, agtc, Gyroscope Therapeutics Limited, SparingVision, Kubota Pharmaceutical Holdings Co. Ltd., REGENXBIO Inc. among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Middle East and Africa Vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.

 


SKU-

TABLE 1 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA INFANTILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA JUVENILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA HOSPITALS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA SPECIALITY CLINICS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA HOME HEALTHCARE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA DIRECT TENDER IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 43 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 SOUTH AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 45 SOUTH AFRICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 46 SOUTH AFRICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 47 SOUTH AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 SOUTH AFRICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 SOUTH AFRICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 SOUTH AFRICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 SOUTH AFRICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 52 SOUTH AFRICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 54 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 55 SOUTH AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 56 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 57 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 58 SAUDI ARABIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 59 SAUDI ARABIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 SAUDI ARABIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 SAUDI ARABIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 62 SAUDI ARABIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 63 SAUDI ARABIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 SAUDI ARABIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 SAUDI ARABIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 SAUDI ARABIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 67 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 68 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 69 SAUDI ARABIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 70 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 71 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 72 U.A.E THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 73 U.A.E GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 74 U.A.E NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 75 U.A.E DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 U.A.E CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 77 U.A.E RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 78 U.A.E ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 U.A.E VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 U.A.E CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 82 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 83 U.A.E RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 84 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 85 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 86 ISRAEL THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 87 ISRAEL GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 88 ISRAEL NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 89 ISRAEL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 90 ISRAEL CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 91 ISRAEL RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 92 ISRAEL ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 93 ISRAEL VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 94 ISRAEL CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 95 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 96 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 97 ISRAEL RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 98 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 99 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 100 EGYPT THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 101 EGYPT GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 102 EGYPT NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 103 EGYPT DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 104 EGYPT CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 105 EGYPT RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 106 EGYPT ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 107 EGYPT VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 108 EGYPT CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 109 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 110 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 111 EGYPT RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 112 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 113 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 114 KUWAIT THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 115 KUWAIT GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 116 KUWAIT NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 117 KUWAIT DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 118 KUWAIT CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 119 KUWAIT RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 120 KUWAIT ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 121 KUWAIT VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 122 KUWAIT CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 123 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 124 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 125 KUWAIT RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 126 REST OF MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The South Africa is the dominating region in the Middle East and Africa Leber Congenital Amaurosis Market.
The Middle East and Africa Leber Congenital Amaurosis Market growth rate is 2.7% during the forecast period.
The Increase in incidence and prevalence of rpe65 gene-mediated in retinal diseases, Increase in pipeline products and clinical trials are the growth drivers of the Middle East and Africa Leber Congenital Amaurosis Market.
The disease type, type, end-user, and distribution channel are the factors on which the Middle East and Africa Leber Congenital Amaurosis Market research is based.
The major companies in the Middle East and Africa Leber Congenital Amaurosis Market are nvitae Corporation, Spark Therapeutics, Inc., LKC Technologies, CENTOGENE N.V., Optos, Metrovision, Blue Print Genetics Oy (A Subsidiary of Quest Diagnostics), CD Genomics, ProQR Therapeutics, OCUGEN, INC., MeiraGTx Limited, Coave Therapeutics, IVERIC bio, Inc. , Atsena Therapeutics, Editas Medicine, Eluminex Biosciences, Okuvision, Astellas Pharma Inc., Allergan, agtc, Gyroscope Therapeutics Limited, SparingVision, Kubota Pharmaceutical Holdings Co. Ltd., REGENXBIO Inc.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials